BioAtla Creates Super-Voting Share for CEO to Force Reverse Stock Split After Failed Shareholder Vote
summarizeSummary
BioAtla, Inc. has created and issued a Super-Voting Series A Junior Preferred Stock to its CEO, granting him the power to ensure the approval of a reverse stock split, following the repeated failure to secure the necessary shareholder votes.
check_boxKey Events
-
Super-Voting Share Issued to CEO
BioAtla issued one Series A Junior Preferred Stock (Super-Voting Share) to its Chairman, CEO, and co-founder, Jay M. Short, Ph.D., for a purchase price of $0.01.
-
Significant Governance Change
The Super-Voting Share grants the holder voting power equal to the total number of common shares outstanding on specific proposals, including a reverse stock split. The holder is required to vote 'for' the proposal if at least two-thirds of the common stock present and entitled to vote approve it.
-
Reverse Stock Split Vote Failed Repeatedly
Shareholders failed to approve a reverse stock split proposal at both the originally convened and reconvened special meetings, despite over 70% of proxies received voting 'FOR' it, due to insufficient total votes.
-
Meeting Adjourned to Force Vote
The special meeting was adjourned again to January 26, 2026, explicitly to allow the Super-Voting Share to be utilized to ensure the approval of the Reverse Stock Split Proposal.
auto_awesomeAnalysis
This filing reveals BioAtla's desperate measures to effect a reverse stock split, likely to maintain its Nasdaq listing. By issuing a single "Super-Voting Share" to the CEO for a nominal fee, the company has effectively bypassed direct shareholder dissent. This share's voting power is tied to the total outstanding common stock and is designed to ensure the reverse split passes if at least two-thirds of *present* common shareholders vote in favor. This move raises significant corporate governance concerns, as it concentrates voting power in the CEO's hands to override the collective will of shareholders on a critical matter. Investors should view this as a strong signal of financial distress and a potential threat to minority shareholder rights.
At the time of this filing, BCAB was trading at $0.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.6M. The 52-week trading range was $0.24 to $1.43. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.